aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
27 sept. 2022 08h00 HE
|
aTyr Pharma, Inc.
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary endpoint will evaluate steroid-sparing effect of efzofitimod compared to placebo. ...
Experience a Pirate’s Life in Multiplayer Arcade Brawler Plunder Panic, Out Now With Crossplay Between All Major Consoles and Windows PC/Mac
16 sept. 2022 10h00 HE
|
Will Winn Games
EAST LANSING, Mich., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Ahoy, Me Hearties! Hoist the Jolly Roger and sharpen those cutlasses, as Will Winn Games’ pirate-themed online multiplayer brawler Plunder...
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
13 sept. 2022 08h00 HE
|
aTyr Pharma, Inc.
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc). SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE)...
aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022
06 sept. 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO , Sept. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022
01 sept. 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
15 août 2022 16h00 HE
|
aTyr Pharma, Inc.
First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis. FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis. Ended the...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 août 2022 16h05 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary...
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
11 août 2022 08h03 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics company engaged in the discovery and development of...
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
04 août 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment
14 juin 2022 08h00 HE
|
aTyr Pharma, Inc.
Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair. Second tRNA synthetase receptor identified from company’s platform. Findings suggest AARS fragment may have...